INTS
INTENSITY THERAPEUTICS, INC.
Next earnings ≈ Jul 28, 2026 · est. from filing cadence
Last earnings -1.9% on 2026-05-07
$4.10
▲ +0.49%$4.10▼ -48.75%
over 1Y
L $3.62EODHDH $33.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.5%
1W+0.5%
1M-8.1%
3M-32.0%
YTD-59.7%
1Y-48.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Conservative balance sheet (liabilities/equity 0.19x).
Return on equity -97.7% · latest
INTENSITY THERAPEUTICS, INC. shows limited reported revenue, and -97.7% ROE.
Financials · annual, by fiscal year
| Line item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$7.55M | -$8.32M | -$16.6M | -$12.0M |
| Net income | -$7.58M | -$10.5M | -$16.3M | -$11.6M |
| Diluted EPS | -$2.22 | -$1.38 | -$29.24 | -$8.56 |
| Net margin | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$1.50M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-111.4%
FCF yield—
Quality & risk
ROIC (est.)-79.6%
Free cash flow—
Total debt—
Net cash$11.9M
Piotroski F-Score4/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-83.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-162026-06-16open ↗8-KPeriod ending 2026-05-072026-05-07open ↗10-QPeriod ending 2026-03-312026-05-07open ↗ARSPeriod ending 2025-12-312026-04-30open ↗DEFA14AFiling2026-04-30open ↗DEF 14APeriod ending 2026-04-302026-04-30open ↗4Period ending 2026-03-262026-03-30open ↗8-KPeriod ending 2026-03-272026-03-27open ↗10-KPeriod ending 2025-12-312026-03-27open ↗8-KPeriod ending 2026-03-232026-03-23open ↗424B5Filing2026-03-23open ↗8-KPeriod ending 2026-03-052026-03-06open ↗
Frequently asked
- Is INTENSITY THERAPEUTICS, INC. (INTS) a buy?
- INTS currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.19x).
- What is INTENSITY THERAPEUTICS, INC.'s quality score?
- INTS scores 57.717948717948715/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001567264, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 7:54:21 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.